XTX Topco Ltd increased its position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 352.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 475,381 shares of the company's stock after purchasing an additional 370,325 shares during the quarter. XTX Topco Ltd owned approximately 0.57% of Editas Medicine worth $551,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in Editas Medicine in the 4th quarter valued at approximately $303,000. Sei Investments Co. purchased a new position in Editas Medicine in the fourth quarter worth $106,000. Prudential Financial Inc. increased its holdings in Editas Medicine by 35.5% in the 4th quarter. Prudential Financial Inc. now owns 196,977 shares of the company's stock worth $250,000 after acquiring an additional 51,600 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Editas Medicine by 2.1% during the 4th quarter. JPMorgan Chase & Co. now owns 787,599 shares of the company's stock valued at $1,000,000 after purchasing an additional 16,419 shares during the period. Finally, Invesco Ltd. increased its position in shares of Editas Medicine by 9.2% during the 4th quarter. Invesco Ltd. now owns 100,164 shares of the company's stock valued at $127,000 after purchasing an additional 8,448 shares during the last quarter. 71.90% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Editas Medicine
In other news, CEO Gilmore Neil O'neill sold 15,192 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $1.72, for a total value of $26,130.24. Following the transaction, the chief executive officer directly owned 280,282 shares of the company's stock, valued at approximately $482,085.04. This represents a 5.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 22,164 shares of company stock worth $42,649 in the last 90 days. 2.10% of the stock is currently owned by insiders.
Editas Medicine Stock Performance
NASDAQ EDIT traded down $0.28 on Friday, reaching $2.21. 2,263,179 shares of the stock traded hands, compared to its average volume of 2,175,397. Editas Medicine, Inc. has a 12 month low of $0.91 and a 12 month high of $4.22. The company has a market cap of $185.01 million, a price-to-earnings ratio of -0.73 and a beta of 2.19. The company has a fifty day moving average price of $2.48 and a 200-day moving average price of $1.82.
Editas Medicine (NASDAQ:EDIT - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.08. The firm had revenue of $4.66 million during the quarter, compared to analyst estimates of $0.79 million. Editas Medicine had a negative return on equity of 139.24% and a negative net margin of 701.06%. During the same period in the previous year, the company posted ($76.00) EPS. As a group, research analysts anticipate that Editas Medicine, Inc. will post -2.71 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts have recently issued reports on EDIT shares. Cantor Fitzgerald raised Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 29th. HC Wainwright started coverage on Editas Medicine in a research note on Monday, April 28th. They set a "buy" rating and a $3.00 target price on the stock. Robert W. Baird reduced their target price on Editas Medicine from $8.00 to $4.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Finally, Wall Street Zen raised Editas Medicine from a "sell" rating to a "hold" rating in a research note on Saturday, July 26th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Editas Medicine presently has a consensus rating of "Hold" and an average price target of $4.70.
View Our Latest Report on Editas Medicine
About Editas Medicine
(
Free Report)
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Recommended Stories
Before you consider Editas Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Editas Medicine wasn't on the list.
While Editas Medicine currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
